Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-2321 and AD-2322 drug-drug interaction study in healthy volunteers
NCT07312799Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fimasartan and chlorthalidone in hypertension (HTN) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve during dosing interval at steady state at Day 14 and Maximum concentration of drug in plasma at steady state at Day 14. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
fimasartanchlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07312799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312799.